WO1997005875A3 - A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus - Google Patents

A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus Download PDF

Info

Publication number
WO1997005875A3
WO1997005875A3 PCT/US1996/012430 US9612430W WO9705875A3 WO 1997005875 A3 WO1997005875 A3 WO 1997005875A3 US 9612430 W US9612430 W US 9612430W WO 9705875 A3 WO9705875 A3 WO 9705875A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
amount
noninsulin
reducing
diabetes mellitus
Prior art date
Application number
PCT/US1996/012430
Other languages
French (fr)
Other versions
WO1997005875A2 (en
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Randall W Whitcomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Randall W Whitcomb filed Critical Warner Lambert Co
Priority to EP96926171A priority Critical patent/EP0851757A2/en
Priority to EA199800177A priority patent/EA199800177A1/en
Priority to IL12219196A priority patent/IL122191A0/en
Priority to AU66411/96A priority patent/AU724989B2/en
Priority to SK164-98A priority patent/SK16498A3/en
Priority to NZ313874A priority patent/NZ313874A/en
Priority to JP9508479A priority patent/JPH11510508A/en
Publication of WO1997005875A2 publication Critical patent/WO1997005875A2/en
Publication of WO1997005875A3 publication Critical patent/WO1997005875A3/en
Priority to BG102235A priority patent/BG102235A/en
Priority to NO980556A priority patent/NO980556L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

This invention provides a method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus by administering to a patient a therapeutically effective amount of a thiazolidione derivative and/or a related compound.
PCT/US1996/012430 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus WO1997005875A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP96926171A EP0851757A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
EA199800177A EA199800177A1 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
IL12219196A IL122191A0 (en) 1995-08-10 1996-07-29 Pharmaceutical compositions containing substituted benzopyrans
AU66411/96A AU724989B2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
SK164-98A SK16498A3 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
NZ313874A NZ313874A (en) 1995-08-10 1996-07-29 Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
JP9508479A JPH11510508A (en) 1995-08-10 1996-07-29 Methods for reducing the amount of exogenous insulin administered to non-insulin dependent diabetes mellitus patients
BG102235A BG102235A (en) 1995-08-10 1998-02-05 Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus
NO980556A NO980556L (en) 1995-08-10 1998-02-09 Procedure for reducing the amount of exogenous insulin administered to a patient with non-insulin-dependent diabetes mellitus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
US60/002,098 1995-08-10

Publications (2)

Publication Number Publication Date
WO1997005875A2 WO1997005875A2 (en) 1997-02-20
WO1997005875A3 true WO1997005875A3 (en) 1997-03-27

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (en)
JP (1) JPH11510508A (en)
KR (1) KR19990036290A (en)
CN (1) CN1192683A (en)
AU (1) AU724989B2 (en)
BG (1) BG102235A (en)
CA (1) CA2221241A1 (en)
CZ (1) CZ32998A3 (en)
EA (1) EA199800177A1 (en)
HU (1) HUP9802543A2 (en)
IL (1) IL122191A0 (en)
NO (1) NO980556L (en)
NZ (1) NZ313874A (en)
SK (1) SK16498A3 (en)
WO (1) WO1997005875A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
FR2838968A1 (en) * 2002-04-30 2003-10-31 Lipha ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139421A1 (en) * 1983-08-30 1985-05-02 Sankyo Company Limited Thiazolidine derivatives, their preparation and compositions containing them
EP0277836A1 (en) * 1987-02-04 1988-08-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139421A1 (en) * 1983-08-30 1985-05-02 Sankyo Company Limited Thiazolidine derivatives, their preparation and compositions containing them
EP0277836A1 (en) * 1987-02-04 1988-08-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
WO1995007697A2 (en) * 1993-09-15 1995-03-23 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 119, no. 1, 5 July 1993, Columbus, Ohio, US; abstract no. 97, "CS-045, an Ameliorator for Insulin Resistance" XP002016853 *
GERBER, P.: "Diabète", MED. HYG. (SWITZERLAND), vol. 53, no. 2053, 4 January 1995 (1995-01-04), pages 22 - 27, XP002016850 *
HOFMANN, C.A. ET AL: "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers", DIABETES CARE, vol. 15, no. 8, 1992, pages 1075 - 1078, XP002016847 *
KANAZAWA ET AL., DIABETES FRONT., vol. 3, no. 6, 1992, pages 570 - 574 *
KARAM, J.H.: "Type II Diabetes and Syndrome X", ENDOCRINOL. METAB. CLIN. NORTH AM. (USA), vol. 21, no. 2, 1992, pages 329 - 350, XP002016852 *
KUZUYA, T. ET AL: "One-Year Clinical Trial of a New Oral Hypoglycemic Agent, CS-045, in NIDDM Patients", DIABETOLOGIA, vol. 37, no. suppl. 1, 1994, pages a63, XP002016849 *
NOLAN, J.J. ET AL: "Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone", N. ENGL. J. MED. (UNITED STATES), vol. 331, no. 18, 1994, pages 1188 - 1193, XP002016851 *
ONUMA, T. ET AL: "The Effect of a New Oral Hypoglycemic Drug, CS-045, on Glucose Tolerance and Serum Lipids in Nonobese Japanese Patients with Non-Insulin-Dependent Diabetes Mellitus: A Pilot Study", CURR. THER. RES. CLIN. EXP. (USA), vol. 55, no. 4, 1994, pages 416 - 421, XP002016848 *

Also Published As

Publication number Publication date
EA199800177A1 (en) 1998-10-29
NZ313874A (en) 2000-09-29
CN1192683A (en) 1998-09-09
EP0851757A2 (en) 1998-07-08
KR19990036290A (en) 1999-05-25
CZ32998A3 (en) 1998-10-14
CA2221241A1 (en) 1997-02-20
WO1997005875A2 (en) 1997-02-20
SK16498A3 (en) 1999-03-12
NO980556D0 (en) 1998-02-09
BG102235A (en) 1998-09-30
IL122191A0 (en) 1998-04-05
NO980556L (en) 1998-02-09
AU6641196A (en) 1997-03-05
AU724989B2 (en) 2000-10-05
JPH11510508A (en) 1999-09-14
HUP9802543A2 (en) 1999-07-28

Similar Documents

Publication Publication Date Title
AU8163394A (en) Treatment of diabetes by administration of myo-inositol
WO1994027587A3 (en) Sustained antiepileptic therapy
AU5309994A (en) Catheter/needle assembly kit and method for administering therapeutic agents to the subarachnoid space
EP0951910A3 (en) Method for administering monomeric insulin analogs
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
YU10799A (en) Aplication of that compound convgs insulotropic activitg or increasos insuline sensitivih for the purpose of produktion of medikcaments
AU5945296A (en) Medicament for nasal administration
AU6286294A (en) Guanidine derivatives useful in therapy
WO1994008580A1 (en) Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
EP0765663A3 (en) Use of dienogest for the manufacture of a medicament for the treatment of the skin by topical application
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
EP0396777A4 (en) Interferon preparation for nasal administration
CA2113856A1 (en) Antidiabetic Agent
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
WO1997005875A3 (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
AU8225391A (en) The use of inositolmonophosphate for the preparing of a medicament effective as a neuropeptide gamma-antagonist
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU1325995A (en) Medical jet injector for administering injections without a needle
AU1173597A (en) Agent for prophylaxis and treatment of diabetic complications
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
MX9709958A (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196191.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG CA CN CZ EE GE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA US UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG CA CN CZ EE GE HU IL JP KR LT LV MX NO NZ PL RO SG SI SK UA US UZ AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2221241

Country of ref document: CA

Ref document number: 2221241

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 313874

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/009958

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996926171

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1998-329

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 16498

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1997 508479

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019980700958

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 199800177

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1996926171

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1998-329

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980700958

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019980700958

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996926171

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-329

Country of ref document: CZ